CAMBRIDGE, Mass., May 28, 2025 - Spero Therapeutics Inc. and GSK plc have announced the early conclusion of their pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The trial ended early following a recommendation from an Independent Data Monitoring Committee, which found that the primary endpoint of non-inferiority compared to intravenous imipenem-cilastatin had been met. The trial involved 1,690 patients and did not reveal any new safety concerns. If approved, tebipenem HBr could become the first oral carbapenem antibiotic available for U.S. patients with cUTIs. Data from the trial will be included in a planned FDA filing in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.